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Background: Health systems are facing the challenge of providing care to an increasing population of patients with cancer.
However, evidence on costs is limited due to the lack of large longitudinal databases.
Methods: We matched cost of care data to population-based, patient-level data on cancer patients in England. We conducted a
retrospective cohort study including all patients age 18 and over with a diagnosis of colorectal (275 985 patients), breast (359 771),
prostate (286 426) and lung cancer (283 940) in England between 2001 and 2010. Incidence costs, prevalence costs, and phase of
care costs were estimated separately for patients age 18–64 and X65. Costs of care were compared by patients staging, before
and after diagnosis, and with a comparison population without cancer.
Results: Incidence costs in the first year of diagnosis are noticeably higher in patients age 18–64 than age X65 across all examined
cancers. A lower stage diagnosis is associated with larger cost savings for colorectal and breast cancer in both age groups. The
additional costs of care because of the main four cancers amounts to d1.5 billion in 2010, namely 3.0% of the total cost of hospital care.
Conclusions: Population-based, patient-level data can be used to provide new evidence on the cost of cancer in England. Early
diagnosis and cancer prevention have scope for achieving large cost savings for the health system.
Many high-income countries, including England and the United
States, are facing the challenge of providing care to an ever
increasing population of patients with cancer (Sullivan et al, 2011).
There are currently 1.8 million people living in England with a
cancer diagnosis (Maddams et al, 2012). According to the latest
projections more than one in three people in England will develop
cancer in their lifetime and there will be an estimated 3 million
people living with cancer in 2030 in England, due to increasing
incidence and improving survivals (National Audit Office, 2015).
These trends are expected to increase pressure on the budget of the
National Health Service (NHS).
Evidence on the cost of cancer should be one of the main pillars
supporting policymakers in achieving the best value for money and
realise an efficient allocation of public resources across different
services and pathways of care. However, there is a dearth of
evidence due to the lack of large databases collecting information
on the cost of care accessed by patients over a sufficiently
long period of time (National Audit Office, 2015). In England,
current evidence is based on a limited number of patients treated
in a restricted number of hospital sites (Hall et al, 2015), or is
based on predicted pathways of care (Incisive Health, 2014).
A number of studies used aggregated utilisation and cost data
(Martin et al, 2008; Luengo-Fernandez et al, 2013; Incisive
Health, 2014), which may affect the accuracy of estimates and
limit the scope for analysis. Some authors deem the shortage of
health economic studies to be a major contributor to the
increasing cancer costs in England and other developed countries
(Sullivan et al, 2011).
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In USA, the availability of the SEER-Medicare database has
empowered researchers and allowed for increased evidence on the
direct costs and economic costs of cancer in the past 20 years
(Brown et al, 1999, 2002; Warren et al, 2008; Yabroff et al, 2008a, b,
2009, 2011; Basu and Manning, 2010). The USA experience
highlights the potential of using population-based, patient-level
databases in investigating a wide range of topics on the cost of
cancer and in producing evidence to inform policymakers and the
wider public. Although SEER-Medicare provides granular data on
health-care utilisation and the costs of care, data are available
only for a proportion of the population in USA age 65 and over.
A recent study from New Zealand using population-based, patient-
level data found higher costs in the age groups under 65 (Blakely
et al, 2015).
In this study, we generate a new database for the analysis of the
cost of cancer in England similar to the SEER-Medicare in the
United States by matching data on the cost of care to data from all
English cancer registries and hospital administrative databases. We
use the new database to estimate incidence and prevalence costs of
cancer in England and compare patterns of care costs in patients
age 18–64 and X65 years old. The use of population-based,
patient-level data allows us to disaggregate our estimates by phases
of care and by stage at diagnosis, and to compare the direct cost of
care in patients with and without cancer in the whole population of
England. To the extent of our knowledge, this is the first time that
such an analysis is made using population-based, patient-level data
in England.
METHODS AND MATERIALS
Data sources. Our study includes data from three main sources:
the National Cancer Data Repository (NCDR); Hospital Episode
Statistics (HES); and the National Schedules of Reference Costs
(NSRC). The NCDR provides information on the characteristics of
patients, including tumour site, age, date of cancer diagnosis and
date of death. HES collects information on patients’ utilisation of
hospital inpatient and outpatient care for all NHS patients in
England; the few non-NHS patients account for o1% of total
hospital income. Our data extract includes all episodes of care
generated by patients in our sample before and after their cancer
diagnosis between 2001 and 2010 (Supplementary Appendix 1).
Finally, the NSRC includes information on the cost of all inpatient
and outpatient services accessed by NHS patients. All NHS
hospitals are mandated to report the cost of every service delivered
to their patients at the end of the fiscal year. Cost data are
disaggregated at the level of HRG (Healthcare Resource Group)
making special adjustments for patients’ type of admission, length
of stay and access to special services, such as renal dialysis,
chemotherapy, radiotherapy and rehabilitation. A detailed descrip-
tion of the NSRC data is included in Supplementary Appendix 2;
the procedure followed to match NSRC with HES data is described
in Supplementary Appendix 3.
Patients. We considered all individuals with a recorded
diagnosis of colorectal cancer (ICD-10 code: C18, C19 and
C20), breast cancer (C50), prostate cancer (C61) or lung cancer
(C33 and C34) in the cancer registries of England between 1
January 2001 and 31 December 2010. We excluded individuals
with age less than 18, or with a previous history of cancer, and
males with breast cancer. We further excluded patients reported
to have died with improper death certificate (DCO) registrations
in line with previous work (Coupland et al, 2011). Our final
sample included 275 985 colorectal cancer patients, 359 771
breast cancer patients, 286 426 prostate cancer patients and
283 940 lung cancer patients.
Outcome measures. The primary outcome measures of this study
were incidence costs, phase of care costs and prevalence costs. The
analysis is based on the cost of hospital activity fixed in 2010.
Incidence costs. Incidence costs are defined as the costs of
delivering care to a homogeneous cohort of patients fixed in the
year of their diagnosis and followed up for a number of years. In
every year following the diagnosis, incidence costs include only
patients who survive the previous year. Although we have registry
data from 2001 to 2010, we have accurate costing data from 2006
to 2010 only. We extend the time window for cost analysis by
including all cohorts diagnosed between 2001 and 2007 using
similar methods to previous work (Brown et al, 1999, 2002).
Firstly, we defined a starting cohort of patients diagnosed with
cancer in 2007 and follow these patients for up to 3 years post
diagnosis and 1 year prior. Secondly, we estimate 4–9-year
incidence costs using hospital activity generated in 2010 by
patients diagnosed between 2001 (9-year incidence cost) and 2006
(4-year incidence cost).
We used inverse probability weights (IPWs) (Hirano and
Imbens, 2001; Wooldridge, 2007) to adjust for the potential
differences between patients in the 2007 cohort and patients in the
2001–2006 cohorts. IPWs allow for greater weight to be given to
the cost estimates of individuals who have similar characteristics to
the 2007 cohort. Similarly, we extended our incidence costs up to 3
years before diagnosis using patients diagnosed in 2008 and 2009.
IPWs were calculated from the propensity scores of a set of logistic
regressions estimated over the differences between the 2007 and
other cohorts. The set of examined covariates include: age; gender;
deprivation; strategic health authority of residence; surgery in first
12 months; and number of hospital admissions in first 12 months.
Little difference was observed between the 2007 diagnosis cohort
and other cohorts.
Phase of care costs. We identified three distinct phases of care by
examining patients with increasing survival times similarly to other
studies (Brown et al, 1999; Yabroff et al, 2008a, 2009):
 The initial phase: the first 6 months immediately following
diagnosis.
 The terminal phase: the final 12 months of life.
 The continuum phase: the time period between the initial and
terminal phase.
In patients surviving no longer than 12 months (e.g., a large
share of lung cancer patients), all costs were allocated to the
terminal phase. To enter the initial phase, a patient must survive at
least 13 months, and to enter the continuum phase, a patient must
survive at least 19 months.
Prevalence costs. Prevalence costs provide a snapshot of the total
costs delivered to all patients in a specific calendar year and include
patients at different points after diagnosis. Prevalence costs are
useful to monitor resources used by patients with a similar cancer
and to plan for appropriate resource allocation in the future.
Prevalence costs were estimated for 2010 by including only patients
who were diagnosed within the previous 5 years (2006–2010).
Costs were estimated for each phase of care (initial, continuum or
terminal).
As this population of patients would still consume health care if
free from cancer, we also compare cancer prevalence costs with the
costs of care in a similar population without cancer. To this end,
we used data on ‘all’ inpatient and outpatient admissions in
England in 2010, data from Census 2011 and a simple
standardisation technique. Firstly, we calculated the total cost of
care accessed by ‘all’ patients aging 18 and over in 2010 (excluding
patients with cancer and their costs) using the same methods for
costing cancer patients and described in Supplementary Material.
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Secondly, we calculated the average cost of care by 5-year age
groups by dividing the total cost in each age group by the total
population in each age group. Finally, we multiply the average
costs in each age group by the total population of cancer patients in
that group.
RESULTS
Patient average incidence costs. Table 1 reports the character-
istics of patients in our sample separately for patients age 18–64
and X65 years old. The latter age group account for a substantial
share of the population affected by the main four cancers: 73.3% of
colorectal; 44.3% of breast; 77.4% of prostate; and 74.7% of lung
cancer patients. Patients age 18–64 have a higher probability of
receiving surgery within 12 month of their diagnosis and also
surviving the first year after diagnosis. Cancer staging was missing
in 24.5% of colorectal and 54.7% of breast cancer patients
and imputed following methods described in Supplementary
Appendix 4. Staging was missing for a large majority of patients
with prostate and lung cancer; hence, we did not report it.
Table 2 reports average incidence costs per patient for patients
age 18–64 and X65, 3 years before and 9 years after their
diagnosis. Costs of care are relatively small 2–3 years pre-diagnosis
across all cancers and age groups and range from d162 per year for
a prostate cancer patient age 18–64 to d542 per year for a lung
cancer patient ageX65. Costs start growing 1 year before diagnosis
ranging between d484 (breast cancer age 18–64) and d1979 (lung
cancer age X65) and peak in the year of diagnosis with marked
differences between age groups. Costs in the year of the diagnosis
reaches d17 241 per patient age 18–64 and d14 776 per patient age
X65 in colorectal cancer, d11 109 and d7788 in breast cancer,
d5171 and d4699 in prostate cancer and d12 083 and d9061 in lung
cancer patients, respectively. Costs reduce in the years following
the diagnosis but remain substantially higher than their pre-
diagnosis level with patients age 18–64 now experiencing smaller
costs as compared with patients age X65.
Table 3 reports average incidence costs per patient for patients
diagnosed with lower stage cancer (stage 1–2) and patients
diagnosed with higher stage cancer (stage 3–4) for colorectal and
breast cancer. Costs are calculated separately for patients age 18–64
and X65 and the difference in costs between lower and higher
stage diagnoses is also reported. We were able to examine patients
with colorectal and breast cancer only, since staging is not reported
in a sufficient number of prostate or lung cancer patients. An early
diagnosis is associated with lower costs in patients with colorectal
and breast cancer both in patients age 18–64 and X65. However,
the potential cost savings associated with an early diagnosis are
greater in patients age 18–64 than in patients age X65. In
colorectal cancer, lower stage diagnosis is associated with  d4276
cost per patient age 18–64 in the first year of diagnosis ( 22.3%
first year costs) as compared with  d1215 cost per patient age
Table 1. Patients’ characteristics in selected cancer sites, 2001–2010
Colorectal Breast Prostate Lung
Total patients 275 985 359771 286 426 283940
Patients age X65 73.3% 44.3% 77.4% 74.7%
Age group 18–64 X65 18–64 X 65 18–64 X65 18–64 X65
Share female 41.5% 46.4% 100.0% 100.0% 0.0% 0.0% 43.3% 42.1%
Average age 55.6 77.1 52.2 76.4 59.2 75.4 57.2 76.4
Stages 1–2 45.8% 52.0% 88.2% 83.5% — — — —
Share in most deprived quintile 17.2% 16.2% 14.9% 15.0% 13.5% 13.8% 28.6% 25.2%
12 month survival 83.1% 65.8% 97.7% 87.8% 97.4% 88.3% 37.1% 25.4%
Surgery in the first 12 monthsa 60.7% 52.2% 77.6% 59.0% 22.0% 4.3% 12.6% 6.9%
a
Surgery was defined using the following OPCS-4 codes: colorectal (H04, H05, H06, H07, H08, H09, H10, H11 and H33); breast (B27 and B28); prostate (M611, M614, M618 and M619); lung (E391,
E398, E399, E441,E461, E541, E542, E543, E544, E545, E548, E549, E552, E554, E559, E574, E578, E595 and T013).
Table 2. Average incidence costs per patient in selected cancer sites. Incidence costs are defined as the total cost of care
delivered to all patients who are alive at the beginning of the considered period
Colorectal (2010 d) Breast (2010 d) Prostate (2010 d) Lung (2010 d)
Age group 18–64 X65 18–64 X65 18–64 X65 18–64 X65
3 Years pre 201 435 165 439 162 375 344 544
2 Years pre 262 471 183 398 224 517 310 542
1 Year pre 1023 1760 484 1126 715 1430 1337 1979
1 Year 17 241 14 776 11 109 7788 5171 4699 12083 9061
2 Years 5014 4231 3676 2675 1965 2705 4540 4320
3 Years 3687 3403 2176 2270 1927 2598 4002 3945
4 Years 2927 2821 1782 2283 1484 2529 2671 3365
5 Years 2388 2769 1708 2186 1559 2593 2551 3043
6 Years 1823 2741 1646 2222 1584 2536 — —
7 Years 1960 2341 1459 2121 1414 3770 — —
8 Years 1688 2630 1432 2144 1501 2782 — —
9 Years 1370 2236 1316 2277 1451 2596 — —
Total (9 Years) 38 098 37 948 26 304 25 966 18056 26808 25847 23734
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X65 (or  7.9%). The total difference in cost 9 years after
diagnosis equals to  d12 577 per patient age 18–64 as compared
with  d4294 per patient age X65. In breast cancer, lower stage
diagnosis is associated with  d2569 lower costs per patient age
18–64 in the first year of diagnosis (or  19.3% of first year costs)
as compared with  d1207 cost per patient age X65 (or  13.7%
of first year costs). The total difference in cost 9 years after
diagnosis equals to  d13 659 per patient age 18–64 as compared
with  d7812 per patient age X65. Differences in the cost of care
between lower and higher staging 2–3 years before the diagnosis
are small both in colorectal and breast cancer. This suggests that
much of the differences in costs emerging after the diagnosis are
explained by differences in cancer staging.
Table 4 shows the differences in the type of care accessed by
patients with lower and higher stage colorectal and breast cancer.
Patients with lower stage colorectal and breast cancer are more
likely to receive surgery within 12 month from their diagnosis with
a positive impact on costs. However, they experience shorter
hospital stay and a lower number of emergency admissions, day
cases and outpatient visits within 12 month of diagnosis. These
factors tend to reduce costs and are likely to explain the difference
in cost reported in Table 3.
Table 3. Average incidence costs per patient by lower and higher stage cancer
Age 18–64 AgeX65
Stages 1–2 Stages 3–4 Difference Stages 1–2 Stages 3–4 Difference
Colorectal (2010 d)
3 Years pre 205 197 8 454 414 40
2 Years pre 267 257 10 453 491 –38
1 Year pre 998 1044  46 1802 1714 88
1 Year 14 911 19 187  4276 14 196 15411  1215
2 Years 3656 6417  2761 3619 5143  1524
3 Years 3069 4449  1380 3034 4065  1031
4 Years 2417 3670  1252 2600 3273  673
5 Years 2195 2676  481 2632 3089  457
6 Years 1566 2272  706 2655 2954  300
7 Years 1620 2615  995 2454 2038 416
8 Years 1502 2051  549 2671 2523 148
9 Years 1323 1472  150 2305 2054 252
Total (9 Years) 33 728 46 306 12577 38 876 43170 4294
Breast (2010 d)
3 Years pre 163 162  2 433 501 68
2 Years pre 171 258 87 376 468 92
1 Year pre 464 607 143 1086 1324 238
1 Year 10 746 13 315 2569 7597 8804 1207
2 Years 3357 5785 2429 2529 3650 1121
3 Years 1953 3782 1829 2156 3170 1014
4 Years 1627 2932 1305 2230 2924 693
5 Years 1617 2841 1225 2077 2957 880
6 Years 1547 2645 1099 2174 2783 609
7 Years 1394 2618 1225 2063 2903 840
8 Years 1376 2559 1183 2134 2454 320
9 Years 1279 1848 569 2204 2932 728
Total (9 Years) 25 693 39 353 13659 27 059 34871 7812
Table 4. Health-care services accessed by patients with lower and higher stage cancer
Age 18–64 AgeX65
Stages 1–2 Stages 3–4 Difference Stages 1–2 Stages 3–4 Difference
Colorectal
Surgery in first 12 months 69.22% 56.28% 12.94% 60.03% 46.55% 13.48%
Total bed days first 12 months 14.36 17.02  2.65 18.91 20.21 1.30
Number of admissions
Ordinary elective 1.13 1.21  0.08 0.94 0.84 0.10
Ordinary emergency 0.64 1.17  0.52 0.72 1.02 0.31
Day case/regular 3.63 7.18  3.56 1.68 3.54 1.86
Outpatient 10.35 13.43  3.08 7.26 8.84 1.58
Breast
Surgery in first 12 months 80.48% 69.98% 10.50% 65.97% 42.37% 23.60%
Total bed days first 12 months 4.28 7.22  2.93 6.50 11.10 4.61
Number of admissions
Ordinary elective 1.10 1.06 0.04 0.83 0.60 0.23
Ordinary emergency 0.36 0.68  0.31 0.34 0.63 0.29
Day case/regular 3.72 5.33  1.61 1.06 1.38 0.32
Outpatient 16.24 16.65  0.42 11.18 10.40 0.78
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Phase of care costs. Figure 1 reports average monthly hospital
costs in cohorts of patients surviving 12–13 months, 24–25 months,
36–37 months, 48–49 months and 60–61 months from diagnosis.
Costs are close to zero before diagnosis with a progressive rise in the
three months before and a stark increase in the month of diagnosis.
The highest average monthly costs are observed in the months
immediately following diagnosis (the ‘initial’ phase) and in the
months immediately preceding death (the ‘terminal’ phase).
Prevalence costs. Table 5 reports 5-year cancer prevalence costs in
2010 for patients with a cancer diagnosis occurring up to 5 years
before. We calculate costs separately for patient age 18–64 and
X65 and partition costs by phases of care (initial, continuum and
terminal). We also compare costs in patients with cancer to costs in
a similar population without cancer.
The highest 5-year prevalence costs are generated by colorectal
patients ageX65 (d459m), followed by breast cancer patients age
18–64 (d426m), prostate cancer ageX65 (d290m) and lung cancer
ageX65 (d267m). The comparison groups allow us to estimate the
additional health-care cost that is due to the cancer condition,
rather than to the other characteristics of patients with cancer, for
example, their age. After subtracting the costs in the comparison
group, prostate cancer is associated with the lowest prevalence
costs both in the population of patients age 18–64 (d56m) and age
X65 (d104m) suggesting that most of the costs are due to the age
of these patients, rather than cancer. Colorectal cancer is still the
most expensive in the population of patients age X65, although
net costs after subtracting comparison group costs are noticeably
lower (d329m), followed by lung cancer (d193m) and breast
(d134m). Breast cancer is the most expensive in the population of
patients age 18–64 (d371m) followed by colorectal (d195m) and
lung (d114m) cancer.
Differences in phase-specific costs are observed across examined
cancers. Initial, continuum and terminal phases cover a similar
share of costs for colorectal cancer for patients age X65. Initial
phase costs absorb a large share of the total cost of care delivered to
patients with colorectal cancer due to high incidence (new cases
diagnosed every year) and high costs of surgical intervention that
follows the diagnosis as displayed in Figure 1. Costs in the
continuum phase absorb a greater proportion of prevalence costs
relative to costs in the initial and terminal phases for prostate and
breast cancer due to a larger proportion of these patients surviving
the initial phase and not entering the terminal phase. Terminal
costs contribute by far the largest share to lung cancer costs owing
to poor survival and a large proportion of patients dying in the year
of their diagnosis.
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Figure 1. Patient average monthly costs: partitioned by survivals.
Table 5. Five-year prevalence costs in selected cancer sites, 2010
Colorectal (2010 d,000s) Breast (2010 d,000s) Prostate (2010 d,000s) Lung (2010 d,000s)
Age group 18–64 X65 18–64 X65 18–64 X65 18–64 X65
Initial 78 520 172 014 164877 88 838 28 213 62 187 34037 60367
Continuum 85 883 139 380 223635 104 489 45 871 144 476 14395 23474
Terminal 52 146 147 293 38173 55 531 9 579 83 827 76685 183253
Total health-care costs (A) 216 549 458 688 426685 248 858 83 663 290 490 125117 267095
Comparison group costs (B) 21 351 129 439 55994 114 716 27 777 186 052 11414 73599
Net health-care costs (A–B) 195 198 329 249 370691 134 142 55 886 104 438 113703 193496
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DISCUSSION
This study expands the scope of existing population-based, patient-
level data to the analysis of the costs of care accessed by patients
with cancer in England. We combined the most granular cost
information available from the NSRC with the NCDR-HES
database creating a new resource for the analysis of the cost of
cancer similar to the well-established SEER-Medicare database in
USA. We processed millions of data records and reconstructed the
patient care pathway retrospectively for each cancer patient in our
sample. The new database has the potential to support a generation
of new research in a similar vein to the success of SEER-Medicare
producing much needed evidence to achieve the efficient allocation
of current and future health resources to the care of patients with
cancer.
We used the new NCDR-HES-RC database to estimate
incidence costs, phase-specific costs and prevalence costs for the
main four cancers in England. We were able to compare costs in
the population of patients age 18–64 andX65 years old. Because of
the lack of appropriate data, there is little evidence of the costs of
care in the former age group both nationally and internationally.
We examined costs by staging, before and after the cancer
diagnosis, and in a comparison population of similar patients
without cancer. We find evidence that the increment in the cost of
care after a cancer diagnosis is markedly higher in patients age 18–
64 as compared with patients age X65 across the four cancers
examined. This is likely to be explained by the higher probability of
receiving surgery for patients in the 18–64 age group. Health-care
costs reduces dramatically after the first year and more markedly in
patients age 18–64 who consume less resources 3 years after
diagnosis as compared with patients age X65. However, costs do
not return to pre-diagnosis levels even 9 years after diagnosis in
both age groups. We also find evidence that a lower stage diagnosis
(stages 1–2) is associated with markedly lower costs as compared
with a higher stage diagnosis (3–4) in patients with colorectal and
breast cancer for whom sufficient data on staging were available.
Although lower staging is associated with higher prevalence of
surgery which may increase costs, we also find evidence that lower
staging is also associated with shorter in-hospital stay, lower
number of emergency admissions and outpatient visits, which are
likely to reduce costs. Our findings suggest that an earlier diagnosis
can generate substantial savings for the health system and even
larger savings if achieved in the population of patients age 18–64.
The younger patients are more likely to get surgery and also more
likely to get offered chemotherapy, which might explain the
broader scope for cost savings. Our evidence can be used to
support existing health interventions aiming at improving the
earlier diagnosis of cancer, such as the urgent GP referrals for
patients with suspect cancer (National Institute for Health and
Care Excellence, 2015) and the colorectal and breast cancer
screening programs.
We identified the costs associated with the initial, the
continuum and the terminal phase of the care pathway. We found
evidence that the cost curve follows a ‘U’ shape distribution with
high cost in the initial phase (first 6 months from diagnosis) and
the terminal phase (last 12 months preceding death) and relatively
low costs during the continuum phase similar to other studies
(Riley et al, 1995; Brown et al, 1999, 2002; Yabroff et al, 2008b,
2011).
Finally, we calculate the additional costs of care due to cancer by
comparing costs in examined cancer cohort with appropriate
comparison groups of individuals without cancer. We elicited the
amount of resources used by cancer patients because of their health
condition from the resources used by the same patients because of
their age and gender. This calculation provides a snapshot of the
total costs to the health system of the care provided to cancer
patients every year excluding the costs that would be incurred had
these people been cancer free. We estimate that colorectal cancer
costed d542 million to the health system in 2010 due to hospital
care, breast cancer d504 million, lung cancer d307 million and
prostate cancer d160 million. The total cost of the main four
cancers to the health system amounts to d1.5 billion in 2010,
namelyB3.0% of the total cost of hospital care in England (d47.3
billion). Most of the existing studies do not elicit the cost of cancer
from the cost of providing care to the cancer population in absence
of cancer making it difficult to assess the impact of the disease on
the resources of the health system. Our evidence provides an
additional support to well-established evidence on the health
outcomes of the population living with cancer and helps in making
informed decisions on the financial scope of health interventions.
Study limitations. Our study presents a number of limitations
due to the secondary data sources used in the analysis; most of
these limitations are expected to fade away as the quality of the
data collected in the HES, NCDR and NSRC improves over time
and new data are added to existing sources. Firstly, our analysis
does not include the costs of primary care, and social care services
since data on utilisation and costs of these services are not available
for the whole population of patients examined in this study. Other
studies estimate that primary care and social care costs are a really
small proportion of total care cost in patients with cancer (Luengo-
Fernandez et al, 2013; Nuffield Trust, 2014).
Secondly, the NCDR data used in our analysis does not report
cancer staging for a large share of patients in our sample reducing
our ability to investigate the impact of staging on costs. We were
able to use imputation techniques to estimate staging in colorectal
and breast cancer, but we could not replicate this exercise in
prostate and lung cancer due to insufficient data on staging
recorded. However, Cancer Registries in England are making
noticeably progress towards the collection of complete staging
information for all cancers and the new release of NCDR data
comes with more complete data on staging.
Finally, the quality of the cost information reported in the NSRC
is variable across different hospitals and over time. We mitigate
variation in data quality by using costs reported at a fixed point in
time (2010), by excluding outliers, and calculating weighted
averages of the costs of similar services reported by different
hospitals (details included in Supplementary Appendix 3).
Although measurement error is reduced using these techniques,
information on cost variation across hospitals and over time is lost.
Following recommendations from the Department of Health, an
increasing number of hospitals are adopting a more sophisticated
system to collect cost information at the level of patient; 50% of
NHS hospital trusts used the new system at the time of our
analysis. The diffusion of the new costing system will improve the
quality of the NSRC data allowing for more granular cost analyses
to be performed in the future.
Future research. The NCDR-HES-RC database offers numerous
opportunities for future research. Our analysis is limited to data on
utilisation of care in 2006–2010 as these were the most recent years
of data available at the time of our study. As more data become
available, new research could be devoted to assess the impact of the
diffusion of new technologies on the cost of care, such as robotic
radical prostatectomy. New studies could examine geographical
variation in the cost of care and provide evidence on the impact of
variation in medical practice and need of care. Finally, new
research could be devoted to assess the impact of different
pathways of care to costs, such as different routes that lead to a
cancer diagnosis.
Improving the quality and the scope of the NCDR-HES-RC
database will be crucial in fostering the new research.
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